share_log

Rodman & Renshaw Initiates Coverage On FibroBiologics With Buy Rating, Announces Price Target of $12

Benzinga ·  Dec 12, 2024 04:03  · Ratings

Rodman & Renshaw analyst Elemer Piros initiates coverage on FibroBiologics (NASDAQ:FBLG) with a Buy rating and announces Price Target of $12.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment